Date | Price Target | Rating | Analyst |
---|---|---|---|
12/2/2022 | $9.00 | Buy | H.C. Wainwright |
10/25/2021 | $12.00 | Buy | Benchmark |
10/25/2021 | $12.00 | Buy | The Benchmark Company |
Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year ("FY25"), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process, but also significantly red
The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to d
Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands Laboratory Capabilities and Launches Advanced AI Models, Aimed at Strengthening Market Position Launches Commercial LENSai API, Offering Advanced AI-Powered Solutions Across Multiple Markets and Prepares for Further Launch with its Newest Partner, AWS ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), an artificial intelligence (AI)-driven biotherapeutic research and technology company, today announced its financial results for the fiscal year ended April 30, 2024. All numbers are expressed in Canadian dollars unless otherwise noted. "IPA has achieved significant
SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
6-K/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year ("FY25"), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process, but also significantly red
The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to d
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's management team invites shareholders and all interested parties to attend. Admission to the Global Investment Conference is free to qualified investors. The Global Investment Conference will be held in-person at the Lotte New York Palace Hotel in Midtown Manhattan, New York, and virtually, from September 9 to September 11, 2024. The Company will be conducting one-on-one meetings. For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA at Quantum
H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00
Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in d
-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. -BioStrand's novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -This proprietary software provides the integration of electronic health records, enhancing AI-driven drug discovery and development for industry professionals. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and t
Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the Company's capacity in performing various label-free protein interaction analyses including best-in-c